Latest News

(UroToday.com) KEYNOTE-199 is a multicohort phase 2 study to evaluate pembrolizumab in mCRPC. A previous analysis of patients with RECIST-measurable (cohort 4) or bone-predominant nonmeasurable (cohort 5) disease who were chemotherapy-naive and had progression while on enzalutamide found that pembrolizumab + enzalutamide showed antitumor activity and manageable safety. Long-term outcomes are of interest with immunotherapy, and […]

(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223) and other targeted agents (including […]

(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer. Following developments in the mCRPC disease space, many of the same treatments have now been adopted in patients with metastatic castration-sensitive disease (mCSPC). Since […]

(UroToday.com) CheckMate 9KD is a phase 2 trial of nivolumab (anti-PD-1) combined with either rucaparib, docetaxel, or enzalutamide for mCRPC. Historically, nivolumab monotherapy has shown minimal clinical activity in unselected populations of patients with mCRPC, potentially secondary to an immunosuppressive prostate tumor microenvironment. PARP inhibitors, like rucaparib, increase cellular DNA damage, particularly in tumors with DNA […]

(UroToday.com) Sabizabulin (VERU-111) is an oral cytoskeletal disruptor that disrupts microtubules supporting the cytoskeleton and has no affinity for multidrug resistance proteins. Additionally, it has been shown to cleave poly (ADTP-ribose) polymerase (PARP) protein, with a favorable toxicity profile with no neurotoxicity and no neutropenia or myelosuppression. The following schematic depicts sabizabulin targeting microtubules and disrupting […]

(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations […]

(UroToday.com) The much anticipated 2021 American Society of Clinical Oncology annual program plenary session included a discussant presentation by Dr. Rana McKay providing her expertise on the recently presented KEYNOTE 564 phase 3 trial with her talk entitled “A Quantum Leap in Cancer Adjuvant Immunotherapy”.

San Francisco, CA (UroToday.com) — Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced positive results from the company’s VAPOR 1 clinical study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for treating […]

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While there are many available treatment options, to date, we have been unable to widely operationalize rationale treatment selection. This has been limited in large part by the lack of head-to-head trials in this […]

(UroToday.com) The bladder cancer oral abstract session at the 2021 American Society of Clinical Oncology annual meeting including a discussant presentation by Dr. Andrea Necchi discussing steps toward a bladder-intact cure for muscle-invasive bladder cancer. Dr. Necchi notes that these steps for a successful outcome include: